Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review

Abstract

Noninvasive diagnostics for portal hypertension include imaging and functional tests, as well as blood-based biomarkers, and capture different features of the portal hypertensive syndrome. Definitive conclusions regarding their clinical utility require assessment of their diagnostic value in specific clinical settings (i.e., diagnosing a particular hemodynamic condition within a well-defined target population). Several noninvasive methods are predictive of clinically significant portal hypertension (CSPH; hepatic venous pressure gradient [HVPG] ≥ 10 mm Hg; the threshold for complications of portal hypertension); however, only a minority of them have been evaluated in compensated advanced chronic liver disease (i.e., the target population). Importantly, most methods correlate only weakly with HVPG at high values (i.e., in patients with CSPH). Nevertheless, selected methods show promise for diagnosing HVPG ≥ 16 mm Hg (the cut-off for increased risks of hepatic decompensation and mortality) and monitoring HVPG changes in response to nonselective beta-blockers or etiological treatments. Finally, we review established and potential future clinical applications of noninvasive methods.

Keywords

cirrhosis - hepatic venous pressure gradient - elastography - von Willebrand factor

Financial Support

No funding specific to this review was received. M.M. was supported by the Andrew K. Burroughs Short-Term Training Fellowship of the European Association for the Study of the Liver.

Publication History

Article published online:
18 June 2020

• References

• 1 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
• 2 Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009; 6 (10) 573-582
• 3 Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J Vis Exp 2019 ; in press
• 4 Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019; 25 (39) 5897-5917
• 5 Mandorfer M, Hernández-Gea V, Reiberger T, García-Pagán JC. Hepatic venous pressure gradient response in non-selective beta-blocker treatment—Is it worth measuring?. Curr Hepatol Rep 2019; 18 (02) 174-186
• 6 Villanueva C, Albillos A, Genescà J. , et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019; 393 (10181): 1597-1608
• 7 Mandorfer M, Kozbial K, Schwabl P. , et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology 2019; [epub ahead of print]
• 8 De Gottardi A, Rautou PE, Schouten J. , et al; VALDIG Group. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol 2019; 4 (05) 399-411
• 9 Berzigotti A, Ashkenazi E, Reverter E, Abraldes JG, Bosch J. Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Dis Markers 2011; 31 (03) 129-138
• 10 Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12 (12) 1791-1798
• 11 Choi SY, Jeong WK, Kim Y, Kim J, Kim TY, Sohn JH. Shear-wave elastography: a noninvasive tool for monitoring changing hepatic venous pressure gradients in patients with cirrhosis. Radiology 2014; 273 (03) 917-926
• 12 Salzl P, Reiberger T, Ferlitsch M. , et al. Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index. Ultraschall Med 2014; 35 (06) 528-533
• 13 Colecchia A, Montrone L, Scaioli E. , et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012; 143 (03) 646-654
• 14 Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003; 229 (02) 409-414
• 15 Thabut D, Imbert-Bismut F, Cazals-Hatem D. , et al. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther 2007; 26 (03) 359-368
• 16 Sandahl TD, McGrail R, Møller HJ. , et al. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. Aliment Pharmacol Ther 2016; 43 (11) 1222-1231
• 17 Hametner S, Ferlitsch A, Ferlitsch M. , et al. The VITRO Score (Von Willebrand factor antigen/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test. PLoS One 2016; 11 (02) e0149230
• 18 Paternostro R, Reiberger T, Bucsics T. Elastography-based screening for esophageal varices in patients with advanced chronic liver disease. World J Gastroenterol 2019; 25 (03) 308-329
• 19 De Gottardi A, Berzigotti A, Buscarini E, García Criado A. Ultrasonography in liver vascular disease. Ultraschall Med 2018; 39 (04) 382-405
• 20 Kim MY, Suk KT, Baik SK. , et al. Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis. Hepatology 2012; 56 (03) 1053-1062
• 21 Amat-Roldan I, Berzigotti A, Gilabert R, Bosch J. Assessment of hepatic vascular network connectivity with automated graph analysis of dynamic contrast-enhanced US to evaluate portal hypertension in patients with cirrhosis: a pilot study. Radiology 2015; 277 (01) 268-276
• 22 Berzigotti A, Piscaglia F, Amat-Roldan I. , et al. Non-invasive measurement of HVPG using graph analysis of dynamic contrast-enhanced ultrasound: the CLEVER study. J Hepatol 2018; 68: S76-S77
• 23 Eisenbrey JR, Dave JK, Halldorsdottir VG. , et al. Chronic liver disease: noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient. Radiology 2013; 268 (02) 581-588
• 24 Schwabl P, Bota S, Salzl P. , et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int 2015; 35 (02) 381-390
• 25 Vizzutti F, Arena U, Romanelli RG. , et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45 (05) 1290-1297
• 26 Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M. Vienna Hepatic Hemodynamic Lab. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol 2012; 47 (05) 561-568
• 27 Augustin S, Millán L, González A. , et al. Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: a prospective study. J Hepatol 2014; 60 (03) 561-569
• 28 Bureau C, Metivier S, Peron JM. , et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008; 27 (12) 1261-1268
• 29 Abraldes JG, Bureau C, Stefanescu H. , et al; Anticipate Investigators. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology 2016; 64 (06) 2173-2184
• 30 Petta S, Sebastiani G, Bugianesi E. , et al. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. J Hepatol 2018; 69 (04) 878-885
• 31 Pérez-Latorre L, Sánchez-Conde M, Rincón D. , et al. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography. Clin Infect Dis 2014; 58 (05) 713-718
• 32 Kitson MT, Roberts SK, Colman JC, Paul E, Button P, Kemp W. Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications. Scand J Gastroenterol 2015; 50 (04) 462-469
• 33 Robic MA, Procopet B, Métivier S. , et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011; 55 (05) 1017-1024
• 34 Cescon M, Colecchia A, Cucchetti A. , et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012; 256 (05) 706-712 , discussion 712–713
• 35 Rajakannu M, Cherqui D, Ciacio O. , et al. Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma. Surgery 2017; 162 (04) 766-774
• 36 Procopet B, Fischer P, Horhat A. , et al. Good performance of liver stiffness measurement in the prediction of postoperative hepatic decompensation in patients with cirrhosis complicated with hepatocellular carcinoma. Med Ultrason 2018; 20 (03) 272-277
• 37 Piecha F, Mandorfer M, Peccerella T. , et al. Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome. Am J Physiol Gastrointest Liver Physiol 2018; 315 (04) G484-G494
• 38 Suh CH, Kim KW, Park SH. , et al. Shear wave elastography as a quantitative biomarker of clinically significant portal hypertension: a systematic review and meta-analysis. AJR Am J Roentgenol 2018; 210 (05) W185-W195
• 39 Elkrief L, Rautou PE, Ronot M. , et al. Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis. Radiology 2015; 275 (02) 589-598
• 40 Procopet B, Berzigotti A, Abraldes JG. , et al. Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. J Hepatol 2015; 62 (05) 1068-1075
• 41 Kim TY, Jeong WK, Sohn JH, Kim J, Kim MY, Kim Y. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients. Liver Int 2015; 35 (11) 2416-2424
• 42 Jansen C, Bogs C, Verlinden W. , et al. Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: a prospective multicentre study. Liver Int 2017; 37 (03) 396-405
• 43 Elkrief L, Ronot M, Andrade F. , et al. Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis. Aliment Pharmacol Ther 2018; 47 (05) 621-630
• 44 Attia D, Schoenemeier B, Rodt T. , et al. Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension. Ultraschall Med 2015; 36 (06) 603-610
• 45 Shen Y, Zhou C, Zhu G. , et al. Liver stiffness assessed by shear wave elastography predicts postoperative liver failure in patients with hepatocellular carcinoma. J Gastrointest Surg 2017; 21 (09) 1471-1479
• 46 Wu D, Chen E, Liang T. , et al. Predicting the risk of postoperative liver failure and overall survival using liver and spleen stiffness measurements in patients with hepatocellular carcinoma. Medicine (Baltimore) 2017; 96 (34) e7864
• 47 Lee JG, Sohn JH, Jeong JY. , et al. Combined effect of hepatic venous pressure gradient and liver stiffness on long-term mortality in patients with cirrhosis. Korean J Intern Med (Korean Assoc Intern Med) 2020; 35 (01) 88-98
• 48 Jansen C, Möller P, Meyer C. , et al. Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. Hepatology 2018; 67 (04) 1472-1484
• 49 Berzigotti A. Non-invasive evaluation of portal hypertension using ultrasound elastography. J Hepatol 2017; 67 (02) 399-411
• 50 Buechter M, Manka P, Theysohn JM, Reinboldt M, Canbay A, Kahraman A. Spleen stiffness is positively correlated with HVPG and decreases significantly after TIPS implantation. Dig Liver Dis 2018; 50 (01) 54-60
• 51 Takuma Y, Nouso K, Morimoto Y. , et al. Portal hypertension in patients with liver cirrhosis: diagnostic accuracy of spleen stiffness. Radiology 2016; 279 (02) 609-619
• 52 Colecchia A, Colli A, Casazza G. , et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. J Hepatol 2014; 60 (06) 1158-1164
• 53 Takuma Y, Morimoto Y, Takabatake H. , et al. Measurement of spleen stiffness with acoustic radiation force impulse imaging predicts mortality and hepatic decompensation in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2017; 15 (11) 1782-1790.e4
• 54 Peng W, Zhang XY, Li C, Wen TF, Yan LN, Yang JY. Spleen stiffness and volume help to predict posthepatectomy liver failure in patients with hepatocellular carcinoma. Medicine (Baltimore) 2019; 98 (18) e15458
• 55 Marasco G, Colecchia A, Colli A. , et al. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. J Hepatol 2019; 70 (03) 440-448
• 56 Gouya H, Grabar S, Vignaux O. , et al. Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging. Eur Radiol 2016; 26 (07) 1981-1990
• 57 Bosch J, Groszmann RJ. Measurement of azygos venous blood flow by a continuous thermal dilution technique: an index of blood flow through gastroesophageal collaterals in cirrhosis. Hepatology 1984; 4 (03) 424-429
• 58 Bosch J, Masti R, Kravetz D. , et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4 (06) 1200-1205
• 59 Motosugi U, Roldán-Alzate A, Bannas P. , et al. Four-dimensional flow MRI as a marker for risk stratification of gastroesophageal varices in patients with liver cirrhosis. Radiology 2019; 290 (01) 101-107
• 60 Ronot M, Lambert S, Elkrief L. , et al. Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis. Eur Radiol 2014; 24 (06) 1394-1402
• 61 Gharib AM, Han MAT, Meissner EG. , et al. Magnetic resonance elastography shear wave velocity correlates with liver fibrosis and hepatic venous pressure gradient in adults with advanced liver disease. BioMed Res Int 2017; 2017: 2067479
• 62 Wagner M, Hectors S, Bane O. , et al. Noninvasive prediction of portal pressure with MR elastography and DCE-MRI of the liver and spleen: preliminary results. J Magn Reson Imaging 2018; 48 (04) 1091-1103
• 63 Asenbaum U, Ba-Ssalamah A, Mandorfer M. , et al. Effects of portal hypertension on gadoxetic acid-enhanced liver magnetic resonance: diagnostic and prognostic implications. Invest Radiol 2017; 52 (08) 462-469
• 64 Haimerl M, Verloh N, Zeman F. , et al. Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: comparison between signal-intensity-based indices and T1 relaxometry. Sci Rep 2017; 7: 43347
• 65 Haimerl M, Probst U, Poelsterl S. , et al. Hepatobiliary MRI: SIGNAL intensity based assessment of liver function correlated to ¹³C-methacetin breath test. Sci Rep 2018; 8 (01) 9078
• 66 Levick C, Phillips-Hughes J, Collier J. , et al. Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: a proof of concept study. PLoS One 2019; 14 (08) e0221066
• 67 Palaniyappan N, Cox E, Bradley C. , et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. J Hepatol 2016; 65 (06) 1131-1139
• 68 Asrani SK, Talwalkar JA, Kamath PS. , et al. Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol 2014; 60 (05) 934-939
• 69 Bastati N, Beer L, Mandorfer M. , et al. Does the functional liver imaging score derived from gadoxetic acid-enhanced MRI predict outcomes in chronic liver disease?. Radiology 2020; 294 (01) 98-107
• 70 Bradley CR, Cox EF, Scott RA. , et al. Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging. J Hepatol 2018; 69 (05) 1015-1024
• 71 Lisotti A, Azzaroli F, Buonfiglioli F. , et al. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology 2014; 59 (02) 643-650
• 72 Møller S, la Cour Sibbesen E, Madsen JL, Bendtsen F. Indocyanine green retention test in cirrhosis and portal hypertension: accuracy and relation to severity of disease. J Gastroenterol Hepatol 2019; 34 (06) 1093-1099
• 73 Pind ML, Bendtsen F, Kallemose T, Møller S. Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis. Eur J Gastroenterol Hepatol 2016; 28 (08) 948-954
• 74 Lisotti A, Azzaroli F, Cucchetti A. , et al. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. Liver Int 2016; 36 (09) 1313-1321
• 75 Schwarz C, Plass I, Fitschek F. , et al. The value of indocyanine green clearance assessment to predict postoperative liver dysfunction in patients undergoing liver resection. Sci Rep 2019; 9 (01) 8421
• 76 Berzigotti A, Seijo S, Arena U. , et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013; 144 (01) 102-111.e1
• 77 Berzigotti A, Gilabert R, Abraldes JG. , et al. Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. Am J Gastroenterol 2008; 103 (05) 1159-1167
• 78 Park SH, Park TE, Kim YM. , et al. Non-invasive model predicting clinically-significant portal hypertension in patients with advanced fibrosis. J Gastroenterol Hepatol 2009; 24 (07) 1289-1293
• 79 Verma V, Sarin SK, Sharma P, Kumar A. Correlation of aspartate aminotransferase/platelet ratio index with hepatic venous pressure gradient in cirrhosis. United European Gastroenterol J 2014; 2 (03) 226-231
• 80 Cho EJ, Kim MY, Lee JH. , et al. Diagnostic and prognostic values of noninvasive predictors of portal hypertension in patients with alcoholic cirrhosis. PLoS One 2015; 10 (07) e0133935
• 81 Procopet B, Cristea VM, Robic MA. , et al. Serum tests, liver stiffness and artificial neural networks for diagnosing cirrhosis and portal hypertension. Dig Liver Dis 2015; 47 (05) 411-416
• 82 Wang L, Feng Y, Ma X. , et al. Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis. PLoS One 2017; 12 (08) e0182969
• 83 Kirnake V, Arora A, Sharma P. , et al. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis. Indian J Gastroenterol 2018; 37 (04) 335-341
• 84 Gressner AM, Tittor W. Serum laminin--its concentration increases with portal hypertension in cirrhotic liver disease. Klin Wochenschr 1986; 64 (23) 1240-1248
• 85 Gressner AM, Tittor W, Negwer A, Pick-Kober KH. Serum concentrations of laminin and aminoterminal propeptide of type III procollagen in relation to the portal venous pressure of fibrotic liver diseases. Clin Chim Acta 1986; 161 (03) 249-258
• 86 Kondo M, Miszputen SJ, Leite-mor MM, Parise ER. The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure levels. Hepatogastroenterology 1995; 42 (05) 542-545
• 87 Kropf J, Gressner AM, Tittor W. Logistic-regression model for assessing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum. Clin Chem 1991; 37 (01) 30-35
• 88 Busk TM, Bendtsen F, Nielsen HJ, Jensen V, Brünner N, Møller S. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scand J Gastroenterol 2014; 49 (09) 1103-1110
• 89 Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J Hepatol 2015; 62 (01) , Suppl): S121-S130
• 90 Grønbaek H, Sandahl TD, Mortensen C, Vilstrup H, Møller HJ, Møller S. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther 2012; 36 (02) 173-180
• 91 Ferlitsch M, Reiberger T, Hoke M. , et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012; 56 (04) 1439-1447
• 92 La Mura V, Reverter JC, Flores-Arroyo A. , et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011; 60 (08) 1133-1138
• 93 Mandorfer M, Schwabl P, Paternostro R. , et al; Vienna Hepatic Hemodynamic Lab. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther 2018; 47 (07) 980-988
• 94 Schwarzer R, Reiberger T, Mandorfer M. , et al. The von Willebrand factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. J Gastroenterol 2019; [epub ahead of print]
• 95 Györi GP, Pereyra D, Rumpf B. , et al. Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation. Hepatology 2019; [epub ahead of print]
• 96 Schwarz C, Fitschek F, Mittlböck M. , et al. von Willebrand factor antigen predicts outcomes in patients after liver resection of hepatocellular carcinoma. Gut Liver 2018
• 97 Bhardwaj A, Kedarisetty CK, Vashishtha C. , et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut 2017; 66 (10) 1838-1843
• 98 Mandorfer M, Peck-Radosavljevic M, Reiberger T. Prevention of progression from small to large varices: are we there yet? An updated meta-analysis. Gut 2017; 66 (07) 1347-1349
• 99 Bruix J, Castells A, Bosch J. , et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111 (04) 1018-1022
• 100 Llop E, Berzigotti A, Reig M. , et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012; 56 (01) 103-108
• 101 Boleslawski E, Petrovai G, Truant S. , et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg 2012; 99 (06) 855-863
• 102 Cucchetti A, Cescon M, Golfieri R. , et al. Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol 2016; 64 (01) 79-86
• 103 Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 2015; 61 (02) 526-536
• 104 European Association for the Study of the Liver. Electronic address: [e-mail]; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
• 105 Piecha F, Peccerella T, Bruckner T, Seitz HK, Rausch V, Mueller S. Arterial pressure suffices to increase liver stiffness. Am J Physiol Gastrointest Liver Physiol 2016; 311 (05) G945-G953
• 106 Zhu Y, Ding H, Fu T. , et al. Portal hypertension in hepatitis B-related cirrhosis: diagnostic accuracy of liver and spleen stiffness by 2-D shear-wave elastography. Hepatol Res 2019; 49 (05) 540-549
• 107 Kim HY, So YH, Kim W. , et al. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. J Hepatol 2019; 70 (03) 412-422
• 108 Reiberger T, Ulbrich G, Ferlitsch A. , et al; Vienna Hepatic Hemodynamic Lab. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013; 62 (11) 1634-1641
• 109 Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis 2017; 49 (01) 3-10
• 110 Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol 2017; 66 (04) 849-859
• 111 Trebicka J, von Heydebrand M, Lehmann J. , et al. Assessment of response to beta-blockers by expression of βArr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. J Hepatol 2016; 64 (06) 1265-1273
• 112 Reverter E, Lozano JJ, Alonso C. , et al. Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver Int 2019; 39 (04) 705-713
• 113 Reiberger T, Püspök A, Schoder M. , et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017; 129 (Suppl. 03) 135-158
• 114 Mandorfer M, Kozbial K, Schwabl P. , et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016; 65 (04) 692-699
• 115 Lens S, Alvarado-Tapias E, Mariño Z. , et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 2017; 153 (05) 1273-1283.e1
• 116 Mandorfer M, Reiberger T, Peck-Radosavljevic M. Monitoring the evolution of portal hypertension after sustained virologic response. Gastroenterology 2018; 154 (05) 1550-1551
• 117 Knop V, Hoppe D, Welzel T. , et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat 2016; 23 (12) 994-1002
• 118 Pons M, Santos B, Simón-Talero M. , et al. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therap Adv Gastroenterol 2017; 10 (08) 619-629
• 119 Pons M, Rodriguez-Tajes S, Esteban JI. , et al. Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals. J Hepatol 2019; [Epub ahead of print]
• 120 Conti F, Buonfiglioli F, Scuteri A. , et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65 (04) 727-733
• 121 Degasperi E, D'Ambrosio R, Iavarone M. , et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol 2019; 17 (06) 1183-1191.e7
• 122 Ravaioli F, Conti F, Brillanti S. , et al. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Dig Liver Dis 2018; 50 (06) 573-579
• 123 Schwabl P, Mandorfer M, Steiner S. , et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther 2017; 45 (01) 139-149
• 124 Ravaioli F, Colecchia A, Dajti E. , et al. Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. World J Hepatol 2018; 10 (10) 731-742
• 125 Haider L, Mandorfer M, Güngören Z. , et al. Noninvasive monitoring of liver disease regression after hepatitis C eradication using gadoxetic acid-enhanced MRI. Contrast Media Mol Imaging 2018; 2018: 8489709
• 126 Bradley C, Scott RA, Cox E. , et al. Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. Eur Radiol 2019; 29 (06) 3100-3107
• 127 Wu S, Kong Y, Piao H. , et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis. Liver Int 2018; 38 (06) 1045-1054
• 128 Seijo S, Reverter E, Miquel R. , et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis 2012; 44 (10) 855-860
• 129 Sharma P, Agarwal R, Dhawan S. , et al. Transient elastography (Fibroscan) in patients with non-cirrhotic portal fibrosis. J Clin Exp Hepatol 2017; 7 (03) 230-234
• 130 Vuppalanchi R, Mathur K, Pyko M, Samala N, Chalasani N. Liver stiffness measurements in patients with noncirrhotic portal hypertension—the devil is in the details. Hepatology 2018; 68 (06) 2438-2440
• 131 Sharma P, Mishra SR, Kumar M, Sharma BC, Sarin SK. Liver and spleen stiffness in patients with extrahepatic portal vein obstruction. Radiology 2012; 263 (03) 893-899
• 132 Madhusudhan KS, Kilambi R. , Shalimar, et al. Measurement of splenic stiffness by 2D-shear wave elastography in patients with extrahepatic portal vein obstruction. Br J Radiol 2018; 91 (1092): 20180401
• 133 Madhusudhan KS, Kilambi R, , Shalimar, Pal S, Sharma R, Srivastava DN. Evaluation of splenic stiffness in patients of extrahepatic portal vein obstruction using 2D shear wave elastography: comparison with intra-operative portal pressure. J Clin Exp Hepatol 2018; 8 (03) 250-255
• 134 Furuichi Y, Moriyasu F, Taira J. , et al. Noninvasive diagnostic method for idiopathic portal hypertension based on measurements of liver and spleen stiffness by ARFI elastography. J Gastroenterol 2013; 48 (09) 1061-1068
• 135 European Association for the Study of the Liver. Electronic address: [e-mail]. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64 (01) 179-202
• 136 Colecchia A, Ravaioli F, Sessa M. , et al. Liver stiffness measurement allows early diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome in adult patients who undergo hematopoietic stem cell transplantation: results from a monocentric prospective study. Biol Blood Marrow Transplant 2019; 25 (05) 995-1003
• 137 Mohty M, Malard F, Abecassis M. , et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2016; 51 (07) 906-912
• 138 Ravaioli F, Colecchia A, Alemanni LV. , et al. Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review. Expert Rev Gastroenterol Hepatol 2019; 13 (05) 463-484
• 139 Richardson PG, Smith AR, Triplett BM. , et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol 2017; 178 (01) 112-118
• 140 Mukund A, Pargewar SS, Desai SN, Rajesh S, Sarin SK. Changes in liver congestion in patients with Budd-Chiari syndrome following endovascular interventions: assessment with transient elastography. J Vasc Interv Radiol 2017; 28 (05) 683-687
• 141 Wang HW, Shi HN, Cheng J, Xie F, Luo YK, Tang J. Real-time shear wave elastography (SWE) assessment of short- and long-term treatment outcome in Budd-Chiari syndrome: a pilot study. PLoS One 2018; 13 (05) e0197550
• 142 Dajti E, Ravaioli F, Colecchia A, Marasco G, Vestito A, Festi D. Liver and spleen stiffness measurements for assessment of portal hypertension severity in patients with Budd Chiari syndrome. Can J Gastroenterol Hepatol 2019; 2019: 1673197
• 143 Xu P, Lyu L, Ge H. , et al. Segmental liver stiffness evaluated with magnetic resonance elastography is responsive to endovascular intervention in patients with Budd-Chiari syndrome. Korean J Radiol 2019; 20 (05) 773-780